pemphigus
Conditions
Interventions
Experimental group:200mg Rituximab
Control group:Immunosuppressants
Control group2:500mg Rituximab
Sponsors
Dermatology Hospital of Southern Medical University, Guangzhou, China
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1) Patients who meet the diagnostic criteria for pemphigus (a: clinical manifestations of skin, mucous membrane flaccid blisters, erosion, Nissl sign positive; b histopathological examination showed intraepidermal blisters and acantholysis; c direct immunofluorescence examination showed acanthocyte IgG, C3 reticular deposition); 2) adult patients aged 18-80 years; 3) mild to moderate pemphigus (PDAI (Pemphigus Disease Area Index, pemphigus disease area index) score, < = 45 points); 4) the first RTX treatment; 5) signed informed consent; 6) can be treated as planned and followed up;
Exclusion criteria
Exclusion criteria: Patients who had previously received RTX or RTX for treatment of relapse; patients aged 80 years; patients with medication contraindications, including severe cardiovascular disease, severe liver and kidney damage, severe active infection, previous severe infusion reactions, history of severe allergy to related drugs, history of cancer, pregnant and lactating women, and recently vaccinated or planned vaccination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pemphigus Disease Area Index;Cumulative hormonal dose;Time to disease control;Time to reach complete response; | — |
Secondary
| Measure | Time frame |
|---|---|
| Percent peripheral blood B lymphocytes;Anti-Dsg3 titer;Anti-Dsg1 titer; | — |
Countries
China
Contacts
Public ContactYongfeng Chen
Dermatology Hospital of Southern Medical University, Guangzhou, China
Outcome results
None listed